dc.contributor.author | Rasche, L | |
dc.contributor.author | Angtuaco, E | |
dc.contributor.author | McDonald, JE | |
dc.contributor.author | Buros, A | |
dc.contributor.author | Stein, C | |
dc.contributor.author | Pawlyn, C | |
dc.contributor.author | Thanendrarajan, S | |
dc.contributor.author | Schinke, C | |
dc.contributor.author | Samant, R | |
dc.contributor.author | Yaccoby, S | |
dc.contributor.author | Walker, BA | |
dc.contributor.author | Epstein, J | |
dc.contributor.author | Zangari, M | |
dc.contributor.author | van Rhee, F | |
dc.contributor.author | Meissner, T | |
dc.contributor.author | Goldschmidt, H | |
dc.contributor.author | Hemminki, K | |
dc.contributor.author | Houlston, R | |
dc.contributor.author | Barlogie, B | |
dc.contributor.author | Davies, FE | |
dc.contributor.author | Morgan, GJ | |
dc.contributor.author | Weinhold, N | |
dc.date.accessioned | 2021-01-12T09:54:08Z | |
dc.date.issued | 2017-07-06 | |
dc.identifier.citation | Blood, 2017, 130 (1), pp. 30 - 34 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4274 | |
dc.identifier.eissn | 1528-0020 | |
dc.identifier.doi | 10.1182/blood-2017-03-774422 | |
dc.description.abstract | 18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the evaluation of malignant plasma cell (PC) disease multiple myeloma (MM). Preliminary observations have suggested that MM patients with extensive disease according to DWIBS may be reported as being disease-free on FDG-PET ("PET false-negative"). The aim of this study was to describe the proportion of PET false-negativity in a representative set of 227 newly diagnosed MM patients with simultaneous assessment of FDG-PET and DWIBS, and to identify tumor-intrinsic features associated with this pattern. We found the incidence of PET false-negativity to be 11%. Neither tumor load-associated parameters, such as degree of bone marrow PC infiltration, nor the PC proliferation rate were associated with this subset. However, the gene coding for hexokinase-2, which catalyzes the first step of glycolysis, was significantly lower expressed in PET false-negative cases (5.3-fold change, P < .001) which provides a mechanistic explanation for this feature. In conclusion, we demonstrate a relevant number of patients with FDG-PET false-negative MM and a strong association between hexokinase-2 expression and this negativity: a finding which may also be relevant for clinical imaging of other hematological cancers. | |
dc.format | Print-Electronic | |
dc.format.extent | 30 - 34 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER SOC HEMATOLOGY | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Multiple Myeloma | |
dc.subject | Hexokinase | |
dc.subject | Fluorodeoxyglucose F18 | |
dc.subject | Neoplasm Proteins | |
dc.subject | False Positive Reactions | |
dc.subject | Positron-Emission Tomography | |
dc.subject | Gene Expression Regulation, Enzymologic | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Female | |
dc.subject | Male | |
dc.title | Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-04-13 | |
rioxxterms.versionofrecord | 10.1182/blood-2017-03-774422 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Blood | |
pubs.issue | 1 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Myeloma Biology and Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.publication-status | Published | |
pubs.volume | 130 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Myeloma Biology and Therapeutics | |
icr.researchteam | Cancer Genomics | |
dc.contributor.icrauthor | Pawlyn, Charlotte | |
dc.contributor.icrauthor | Houlston, Richard | |